The compulsory licence issued to Natco for manufacture of the anti-cancer drug Nexavar is a landmark decision on many grounds – the first one in India since the 2005 amendment to the 1970 Patents Act and the fi rst in the world issued to a private party. There are some ambiguities in the order, but the door is now open for issue of CLs for a number of patented drugs that are not being worked.
Links:
[1] http://admin.indiaenvironmentportal.org.in/feature-article/compulsory-licence-nexavar-landmark-order
[2] http://admin.indiaenvironmentportal.org.in/category/author/s-srinivasan
[3] http://admin.indiaenvironmentportal.org.in/category/journal/economic-and-political-weekly
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/india
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/cancer
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/patents
[9] http://admin.indiaenvironmentportal.org.in/category/thesaurus/legislation
[10] http://admin.indiaenvironmentportal.org.in/category/thesaurus/bayer-pharmaceuticals
[11] http://admin.indiaenvironmentportal.org.in/category/thesaurus/patent-rules-2005
[12] http://admin.indiaenvironmentportal.org.in/category/thesaurus/private-sector